Key facts
- It has raised $190K; the latest was Early Stage VC ($190K) in Mar 2026.
- Notable investors include Venture Kick, Innovation Office (Accelerator/Incubator).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for NZM
- ·The full record, as it builds
Funding rounds
No funding rounds for NZM are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NZM
Developer of lipid nanoparticle-based enzyme delivery technology intended to improve treatment of lysosomal storage disorders. The company enhances intracellular uptake, protects enzymes from immune reactions, supports targeted lysosomal release, increases functional activity in key tissues, and adapts delivery mechanisms across multiple rare diseases, enabling biotechnology partners to advance more effective therapies.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Employees
- 4
- Website
- nanozymex.com/
- Ownership
- Privately Held (backing)
NZM doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NZM shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NZM in its N-PORT filings yet. We sweep new filings monthly.